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Abstract
There is accumulating evidence for the efficacy of lamotrigine in the treatment
of bipolar disorder, including bipolar depression, both as monotherapy and
in combination with sodium valproate. We present the cases of 3 female
patients admitted to our hospital with the diagnosis of schizoaffective disorder
who were treated with lamotrigine. While dosages up to 200 mg/day, resulting
in serum concentrations of less than 5 mg/l, were only partially effective,
400 mg/day (with serum concentrations ?10 mg/l) led to considerable mood
stability, with complete remission from paranoid symptoms. We suggest that
lamotrigine might be helpful in the treatment of schizoaffective disorder,
probably with serum concentrations of more than 5 mg/l.
.......................
Recently, considerable evidence has accumulated that Case Reports
lamotrigine is effective in the treatment of bipolar dis-
Case 1
order, both as monotherapy [1] and in combination with This 33-year-old bank clerk was admitted 9/97 with a severe
valproate [2], a drug known to markedly increase blood schizomanic episode. She was previously diagnosed as schizoaffective
levels of lamotrigine [3]. In particular, lamotrigine might disorder, having 6 schizomanic episodes since age 21, with full remis-
sion in between. Originally, the disorder started with a severe depres-be helpful in treatment-refractory bipolar disorder [4–6],
sion and a suicide attempt in 1986. The patient continuously tookrapid-cycling bipolar disorder [7, 8], bipolar depression
lithium since 1993, the last schizomanic episodes were 3/97 and 9/97.[9–11] and bipolar mania [12].
Lithium was discontinued because of the lack of efficacy, hypothyroid-Here we report on 3 female patients admitted to the
ism and weight gain. The acute schizomanic episode was treated
Munich University Psychiatric Hospital with the diagno- successfully with a sodium valproate loading therapy. After discharge
sis of schizoaffective disorder who were consecutively 12/97, the patient developed a severe loss of hair and lamotrigine
treated with lamotrigine as monotherapy. All patients was introduced with the aim of substituting for sodium valproate.
Lamotrigine was well tolerated and in 2/98 a serum concentration ofhad experienced numerous episodes in the past and were
4.8 mg/l was reached with 125 mg of LamictalÔ. At this point, thenot responsive to lithium and/or did not tolerate sodium
patient developed a light manic episode without paranoid symptomsvalproate. Depressive episodes in the past had frequently
which led to admission to our hospital; it was important for therequired use of antidepressants with the consecutive risk
patient that this was the first time she was not admitted against
to induce a new schizomanic episode. her will. Manic symptoms were considerably diminished by further
increasing lamotrigine serum concentrations (9.3 mg/l, administration
of 400 mg Lamictal).
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Case 2 Discussion
Mrs. L. is a 31-year-old opera singer who was admitted to our
hospital in 11/97 with the diagnosis of schizomanic episode. In the The history of these patients shows that lamotrigine
past 10 years at least 3 depressive and 2 manic episodes were observed
can be used safely and successfully in treatment-resistantwith full remission in between, at this time she also exhibited severe
schizoaffective disorder. Because of the risk of skin rashesthought disorder, delusions and hallucinations leading to a ICD-
lamotrigine – unlike sodium valproate – cannot be given10 diagnosis of schizomanic episode. The patient, who is a lithium
nonresponder, received lamotrigine. Termination of the schizomanic as a loading therapy. Our cases suggest that, unless serum
episode was achieved with dosing up to 300 mg/day Lamictal, leading concentrations of more than 5 mg/l are reached, lamotri-
to a serum concentration of 7.7 mg/l. After discharge a very light gine does not seem to display its full protective action.
depression was observed, no antidepressant medication was necessary. It might be useful to initially combine lamotrigine with
other potentially efficacious substances. Once dosed up
Case 3
to approximately 400 mg/day, lamotrigine in our patientsThe 37-year-old cosmetician was admitted in 6/97 with a severe
seemed to be effective in a variety of schizoaffective symp-schizomanic episode. Since 1979 the patient was admitted at least 40
toms as paranoid symptoms, hallucinations, thought dis-times in different psychiatric hospitals because of mania, severe depres-
sion or schizomania. In the last 3 years no full remission was achieved order, manic and depressive symptoms. The efficacy of
as a rapid cycling between (schizo)mania and depression had to be ob- lamotrigine in treating the schizophrenic component
served despite several therapeutic attempts to influence the disease. Li- parallels the reduction of ketamine effects in healthy hu-
thium was not able to prevent severe manic episodes, carbamazepine mans reported by Anand et al. [13] and might be mediated
was equally ineffective and sodium valproate led to hair loss. The epi-
by reduction of glutamate release. The efficacy of lamotri-sode in 6/97 was treatment-resistant to high doses of flupentixol as well
gine in reducing depressive symptoms might be linked toas to 25 mg of olanzapine. A therapy with lamotrigine was started and
5-HT uptake inhibition, an effect described in both ratdischarge was possible in 8/97. Unfortunately, in 12/97 depression and
severe suicidal thoughts developed despite 200 mg of Lamictal mono- and human tissue by Southam et al. [14].
therapy (serum concentration of 2.4 mg/l), consecutively lamotrigine In summary, further studies and long-term observa-
was combined with 150 mg of venlafaxine. This strategy led to induc- tion of the effects of high doses of lamotrigine are neces-
tion of a new schizomanic episode. At this point, venlafaxine was dis- sary; because of its dual action on both glutamate and 5-
continued and cis-clopentixol added to lamotrigine. In 1/98 discharge
HT neurotransmission, lamotrigine might be particularlywas possible, the last serum concentration of lamotrigine was 5.1 mg/
useful in the treatment of schizoaffective disorder.ml (400 mg Lamictal). Cis-clopentixol was discontinued. In 3/98 a light
depression without suicidal thoughts was observed, no antidepressant
drug was prescribed at this point.
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